Cargando…

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses

Detalles Bibliográficos
Autores principales: Bitoun, Samuel, Avouac, Jérôme, Henry, Julien, Ghossan, Roba, Al Tabaa, Omar, Belkhir, Rakiba, Nocturne, Gaetane, Mariaggi, Alice Andrée, Rozenberg, Flore, Vauloup-Fellous, Christelle, Mariette, Xavier, Seror, Raphaèle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121105/
https://www.ncbi.nlm.nih.gov/pubmed/35589332
http://dx.doi.org/10.1136/rmdopen-2022-002308
_version_ 1784711084950683648
author Bitoun, Samuel
Avouac, Jérôme
Henry, Julien
Ghossan, Roba
Al Tabaa, Omar
Belkhir, Rakiba
Nocturne, Gaetane
Mariaggi, Alice Andrée
Rozenberg, Flore
Vauloup-Fellous, Christelle
Mariette, Xavier
Seror, Raphaèle
author_facet Bitoun, Samuel
Avouac, Jérôme
Henry, Julien
Ghossan, Roba
Al Tabaa, Omar
Belkhir, Rakiba
Nocturne, Gaetane
Mariaggi, Alice Andrée
Rozenberg, Flore
Vauloup-Fellous, Christelle
Mariette, Xavier
Seror, Raphaèle
author_sort Bitoun, Samuel
collection PubMed
description
format Online
Article
Text
id pubmed-9121105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91211052022-05-20 Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses Bitoun, Samuel Avouac, Jérôme Henry, Julien Ghossan, Roba Al Tabaa, Omar Belkhir, Rakiba Nocturne, Gaetane Mariaggi, Alice Andrée Rozenberg, Flore Vauloup-Fellous, Christelle Mariette, Xavier Seror, Raphaèle RMD Open Infections BMJ Publishing Group 2022-05-18 /pmc/articles/PMC9121105/ /pubmed/35589332 http://dx.doi.org/10.1136/rmdopen-2022-002308 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Infections
Bitoun, Samuel
Avouac, Jérôme
Henry, Julien
Ghossan, Roba
Al Tabaa, Omar
Belkhir, Rakiba
Nocturne, Gaetane
Mariaggi, Alice Andrée
Rozenberg, Flore
Vauloup-Fellous, Christelle
Mariette, Xavier
Seror, Raphaèle
Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
title Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
title_full Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
title_fullStr Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
title_full_unstemmed Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
title_short Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
title_sort very low rate of humoral response after a third covid-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses
topic Infections
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121105/
https://www.ncbi.nlm.nih.gov/pubmed/35589332
http://dx.doi.org/10.1136/rmdopen-2022-002308
work_keys_str_mv AT bitounsamuel verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT avouacjerome verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT henryjulien verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT ghossanroba verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT altabaaomar verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT belkhirrakiba verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT nocturnegaetane verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT mariaggialiceandree verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT rozenbergflore verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT vauloupfellouschristelle verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT mariettexavier verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses
AT serorraphaele verylowrateofhumoralresponseafterathirdcovid19vaccinedoseinpatientswithautoimmunediseasestreatedwithrituximabandnonresponderstotwodoses